DSIP (Delta-Sleep-Inducing Peptide)
Promotes deep, restorative sleep naturally
- Improved Sleep Quality
- Stress Reduction
- Anxiety Relief
Virtually no controlled human safety data exists — most knowledge derives from Soviet-era research and anecdotal reports Long-term effects on sleep physiology and neuroendocrine function are completely unknown Peptide purity from unregulated sources cannot be verified, introducing additional unknown risks Not approved for human use by any major regulatory agency
Mechanism of Action
DSIP (Delta-Sleep-Inducing Peptide) is a 9-amino acid neuropeptide that appears to modulate sleep architecture through interactions with central nervous system receptors, though its exact molecular targets remain incompletely characterized. It is proposed to influence GABAergic and serotonergic neurotransmission, and may affect the hypothalamic-pituitary-adrenal axis to reduce cortisol and stress hormone levels. The peptide was originally isolated from rabbit brain tissue during induced sleep states in the 1970s. Key Pathways: GABAergic neurotransmission modulation, Hypothalamic-pituitary-adrenal (HPA) axis regulation, Serotonergic system interactions, Endogenous opioid system crosstalk If DSIP's proposed mechanisms are accurate, users might experience improved sleep onset and enhanced slow-wave (delta) sleep phases, along with reduced stress and anxiety through HPA axis modulation. However, the connection between its molecular actions and subjective sleep improvement remains poorly validated in controlled human studies.
Common Dose Reference Ranges
Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.
Full DSIP (Delta-Sleep-Inducing Peptide) protocols — frequency, timing, cycle length, reconstitution & research
- Morning grogginess or drowsiness
- Headache
- Injection site reactions
- Transient hypotension
- Paradoxical sleep disturbance
- Unknown long-term effects